Position in EXEL
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$297,699
-$71,656 QoQ
Shares Held
6,941
-17.6% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ROTHSCHILD INVESTMENT LLC holds $5,484,521 across 220 Biotechnology names. EXEL ranks #6 (5.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,486 | $1,148,143 | |
| 2 | TECH |
BIO-TECHNE Corp
|
18,736 | $979,143 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
7,865 | $444,293 | |
| 4 | INCY |
Incyte Corp
|
4,540 | $427,304 | |
| 5 | CGEN |
Compugen Ltd
|
140,600 | $299,478 | |
| 6 | EXEL |
Exelixis, Inc.
This page
|
6,941 | $297,699 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
437 | $195,137 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
883 | $166,931 |
All Filings in EXEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $297,699 | 6,941 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $369,355 | 8,427 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $199,561 | 4,832 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $220 | 5 | Shares | Sole | 2025-08-11 | |
| No filing history on record for this holder in this stock. | ||||||